Shao-Lee Lin, Acelyrin CEO

Ace­lyrin tops its $250M crossover with new $300M cash raise from blue-chip syn­di­cate

Shao-Lee Lin and her LA-based team at Ace­lyrin are back — and bring­ing its largest fi­nanc­ing haul yet.

The biotech re­port­ed a $300 mil­lion Se­ries C round Tues­day morn­ing, send­ing the com­pa­ny over the half-bil­lion dol­lar mark in ven­ture fi­nanc­ing since it was found­ed more than two years ago. The goal, ac­cord­ing to the biotech, is to push for­ward Phase III de­vel­op­ment of so-far sole can­di­date izok­ibep — in pso­ri­at­ic arthri­tis and ax­i­al spondy­loarthri­tis — through BLA sub­mis­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.